Therapy trials with bacterial compounds in irritable bowel syndrome (IBS) have produced conflicting results.
Dr Enck and colleagues treated 297 patients with lower abdominal symptoms diagnosed as irritable bowel syndrome (IBS) for 8 weeks by the compound ProSymbioflor® or placebo in a double-blinded, randomized fashion.
The researchers undertook autolysates of cells and cell fragments of Enterococcus fecalis and Escherichia coli.
Patients were seen weekly by the physician, who assessed the presence of core irritable bowel syndrome symptoms.
|The responder rate in global symptom score to the drug was 69%|
|Neurogastroenterology & Motility|
The researchers found responders had at least a 50% decrease in global symptom score and in abdominal pain score reports at the first visit during treatment.
The responder rate in global symptom score to the drug was 69% in comparison to placebo with 38%.
The improvement in abdominal pain score was 73% and 45%, respectively.
The number-needed-to-treat was 3.3 for global symptom score, and 3.6 for the abdominal pain score report.
Kaplan–Meier analysis revealed a mean response time of 4 to 5 weeks for active treatment and more than 8 weeks for placebo.
Dr Enck’s team concluded, “Treatment of irritable bowel syndrome with the bacterial lysate ProSymbioflor is effective and superior to placebo in reducing typical symptoms of irritable bowel syndrome patients seen by general practitioners.”